Hand Me Down Fundraiser

The Eli Lilly company has been marketing a new drug for those who are labeled as ADHD known as Strattera. This drug is purported to be a non-stimulant medication, however the side effects are similar. Rather than effecting the dopamine system as do the stimulants such as methylphenidate and dextroamphetamine, it works upon the norepinephrine neurotransmitter. Strattera is considered a Norepinephrine reuptake inhibitor. Norepinephrine is the brain’s adrenalin. Norephinephrine is involved in the increased rate and force of the heart muscle, constriction of heart muscles, pulmonary function (Hedaya, 1999). If these functions are increased, it would be evident that Strattera could produce possible untoward effects on the cardiovascular system. It is interesting to note that in the safety information that Eli Lilly provides on its website, it refers to possible hazards to those who have heart disease or high blood pressure. Information p natural skin care rovided by Eli Lilly accompanying prescriptions of this drug note the possibility of tachycardia, and increased blood pressure. Tourette’s disorder, though the etiology is not fully known is being examined as difficulties arising in the metabolism of dopamine, serotonin, and norepinephrine. it is known that stimulant drugs can produce Tourette’s like behavior in some children (Breggin, 1998). If Strattera affects the norepinephrine system, then it would seem evident that the possibility of such Tourette’s like behavior could also become manifest in some children using Strattera. Therefore, though Strattera is being marketed in the fashion of being a non-stimulant drug, its ill effects are quite similar to that manifested by the stimulant medications. Eli Lilly’s website notes that growth suppression is a common side effect and needs to be monitored in children making use of this drug. Loss of appetitite and weight loss is also seen.